These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36118157)

  • 21. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.
    Blum K; Chen TJ; Meshkin B; Waite RL; Downs BW; Blum SH; Mengucci JF; Arcuri V; Braverman ER; Palomo T
    Med Hypotheses; 2007; 69(5):1054-60. PubMed ID: 17467918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.
    Blum K; Baron D; McLaughlin T; Thanos PK; Dennen C; Ceccanti M; Braverman ER; Sharafshah A; Lewandrowski KU; Giordano J; Badgaiyan RD
    J Addict Psychiatry; 2024 Apr; 8(1):1-33. PubMed ID: 38765881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study.
    Demarin V; Podobnik SS; Storga-Tomic D; Kay G
    Drugs Exp Clin Res; 2004; 30(1):27-33. PubMed ID: 15134388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.
    Blum K; Modestino EJ; Neary J; Gondré-Lewis MC; Siwicki D; Moran M; Hauser M; Braverman ER; Baron D; Steinberg B; Laughlin TM; Badgaiyan RD
    Biomed J Sci Tech Res; 2018 Jan; 2(2):1-4. PubMed ID: 30370423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Craving and Depressive Symptoms in Ketamine-Dependent Patients Undergoing Withdrawal Treatment.
    Chen LY; Chen CK; Chen CH; Chang HM; Huang MC; Xu K
    Am J Addict; 2020 Jan; 29(1):43-50. PubMed ID: 31691402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EMDR as Add-On Treatment for Psychiatric and Traumatic Symptoms in Patients with Substance Use Disorder.
    Carletto S; Oliva F; Barnato M; Antonelli T; Cardia A; Mazzaferro P; Raho C; Ostacoli L; Fernandez I; Pagani M
    Front Psychol; 2017; 8():2333. PubMed ID: 29375445
    [No Abstract]   [Full Text] [Related]  

  • 27. Sobriety and Satiety: Is NAD+ the Answer?
    Braidy N; Villalva MD; van Eeden S
    Antioxidants (Basel); 2020 May; 9(5):. PubMed ID: 32423100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the validity and reliability of the Turkish versions of craving beliefs and beliefs about substance use questionnaire in patients with heroin use disorder: demonstrating valid tools to assess cognition-emotion interplay.
    Küçükkarapınar M; Eser HY; Kotan VO; Yalcinay-Inan M; Tarhan R; Arikan Z
    Subst Abuse Treat Prev Policy; 2018 Aug; 13(1):29. PubMed ID: 30134921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and Preliminary Evaluation of an Integrated Cognitive-Behavior Treatment for Chronic Pain and Substance Use Disorder in Patients with the Hepatitis C Virus.
    Morasco BJ; Greaves DW; Lovejoy TI; Turk DC; Dobscha SK; Hauser P
    Pain Med; 2016 Dec; 17(12):2280-2290. PubMed ID: 28025362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anhedonia, depression, anxiety, and craving in opioid dependent patients stabilized on oral naltrexone or naltrexone implant].
    Krupitsky EM; Zvartau EE; Blokhina EA; Verbitskaya EV; Wahlgren VY; Tsoy-Podosenin MV; Bushara NM; Burakov AM; Masalov DV; Romanova TN; Tiurina AA; Palatkin VY; Yaroslavtseva TS; Sulimov GY; Pecoraro A; Woody G
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(1. Vyp. 2):26-33. PubMed ID: 29658501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis".
    Braverman ER; Dennen CA; Gold MS; Bowirrat A; Gupta A; Baron D; Roy AK; Smith DE; Cadet JL; Blum K
    Int J Environ Res Public Health; 2022 Apr; 19(9):. PubMed ID: 35564876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome - A randomized, controlled, double-blind trial.
    Castro-Marrero J; Sáez-Francàs N; Segundo MJ; Calvo N; Faro M; Aliste L; Fernández de Sevilla T; Alegre J
    Clin Nutr; 2016 Aug; 35(4):826-34. PubMed ID: 26212172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.
    Blum K; Chen AL; Chen TJ; Braverman ER; Reinking J; Blum SH; Cassel K; Downs BW; Waite RL; Williams L; Prihoda TJ; Kerner MM; Palomo T; Comings DE; Tung H; Rhoades P; Oscar-Berman M
    Theor Biol Med Model; 2008 Nov; 5():24. PubMed ID: 19014506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exogenous Nicotinamide Adenine Dinucleotide Attenuates Postresuscitation Myocardial and Neurologic Dysfunction in a Rat Model of Cardiac Arrest.
    Su C; Xiao Y; Zhang G; Liang L; Li H; Cheng C; Jin T; Bradley J; Peberdy MA; Ornato JP; Mangino MJ; Tang W
    Crit Care Med; 2022 Feb; 50(2):e189-e198. PubMed ID: 34637412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
    Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
    Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A meta-analysis of craving studies in schizophrenia spectrum disorders.
    Dondé C; Achim AM; Brunelin J; Poulet E; Mondino M; Haesebaert F
    Schizophr Res; 2020 Aug; 222():49-57. PubMed ID: 32553432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired nicotinamide adenine dinucleotide (NAD
    Fan L; Cacicedo JM; Ido Y
    J Diabetes Investig; 2020 Nov; 11(6):1403-1419. PubMed ID: 32428995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual.
    Blum K; Lott L; Baron D; Smith DE; Badgaiyan RD; Gold MS
    J Syst Integr Neurosci; 2020 May; 7():. PubMed ID: 32934823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair.
    Fried L; Modestino EJ; Siwicki D; Lott L; Thanos PK; Baron D; Badgaiyan RD; Ponce JV; Giordano J; Downs WB; Gondré-Lewis MC; Bruce S; Braverman ER; Boyett B; Blum K
    Curr Pharm Biotechnol; 2020; 21(6):528-541. PubMed ID: 31820688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic.
    Tsuang D; Cowley D; Ries R; Dunner DL; Roy-Byrne PP
    J Clin Psychiatry; 1995 Dec; 56(12):549-55. PubMed ID: 8530330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.